- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Galectin-3: a prognostic biomarker in patients with COVID-19 acute respiratory failure
Overview
Galectin-3 can provide important prognostic information in patients with COVID-19 acute respiratory failure, according to a study published in the Journal of Respiratory Medicine.
Galectin-3 is β-galactoside-binding lectin with several roles in immune-inflammatory response. Recently, Galectin-3, a β-galactoside-binding lectin, has raised some interest as a potential marker of lung damage and a possible therapeutic target in COVID-19 disease.
Galectin-3 has pleiotropic effects on the immune response: it modulates immune cells lifecycle, angiogenesis and reparative response after lung injury. To date, there is no evidence of Galectin-3 role as a prognostic biomarker in COVID-19 disease.
AndreaPortacci and colleagues from the Institute of Respiratory Disease, Cardio-Thoracic Department, University of Medicine, Bari, Italy aimed to clarify the prognostic role of Galectin-3 in patients with COVID 19 acute respiratory failure.
The team of investigators enrolled 156 consecutive patients with COVID-19 disease. Routine laboratory test, arterial blood gas, chest X-ray or Computed Tomography and Galectin-3 dosage were performed.
The primary outcome was to assess Galectin-3 predictive power for 30-day mortality. Secondary outcomes were 30-day Intensive Care Unit admission and Acute Respiratory Distress Syndrome stratification according to Galectin-3 dosage.
The authors performed Mann-Whitney U and Kruskal-Wallis tests for continuous variables comparison. Fisher's exact test or Chi-square test were used for categorical variables analysis.
Receiver Operating Characteristic curves estimated Galectin-3 predictive power for the endpoints. With a fixed cut-off of 35.3 ng/ml, Kaplan-Meier with Log-Rank test and Cox Regression were performed to assess mortality and Intensive Care Unit admission risk.
The findings of the study revealed that Galectin-3 correlated with many other prognostic predictors tested in the present analysis. Moreover, patients with serum levels of Galectin-3 above 35.3 ng/ml had increased risk for mortality, Intensive Care Unit admission and severe Acute Respiratory Distress Syndrome.
As a result, the authors concluded that Galectin-3 can be used as a predictor of mortality, Intensive Care Unit access and ARDS stratification in patients with COVID 19 acute respiratory failure.
They further inferred that increased Galectin- 3 serum levels are associated with higher risk of death, ICU access and severe ARDS development.
https://doi.org/10.1016/j.rmed.2021.106556
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)